Comparison of risk of cerebrovascular events in an elderly VA population with dementia between antipsychotic and nonantipsychotic users

被引:32
作者
Barnett, Mitchell J.
Wehring, Heidi
Perry, Paul J.
机构
[1] Touro Univ Calif, Coll Pharm, Vallejo, CA 94592 USA
[2] Vet Adm Hosp, Ctr Res Implementat Innovat Strategies Practice, Iowa City, IA USA
关键词
D O I
10.1097/jcp.0b013e31815a2531
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: The credibility of an increased risk of cerebrovascular events (CVEs) in elderly patients with dementia being treated with second-generation antipsychotics (SGAs) is debatable. Although early published and unpublished data indicated a risk, much of the subsequent literature has not supported this initial finding. Previously published studies were flawed in part because they lacked a control group and did not stratify by dementia subtype. This study examined the risk of a CVE in patients diagnosed with Alzheimer or vascular dementia while being treated with SGA, first-generation antipsychotics, or no antipsychotic medication. Methods: Data from 14,029 patients aged 65 years and older were evaluated using patient information from Veterans Administration and Medicare databases. Patients who received care for dementia were categorized according to dementia subtype (vascular or Alzheimer) and antipsychotic use during an 18-month period. Patients were observed until they were admitted to a hospital for a CVE, stopped taking or switched antipsychotics, died, or until the 18-month observation period ended. Results: Overall, CVE risk did not differ whether patients were receiving a first-generation antipsychotic, SGA, or no antipsychotic therapy. However, patients with vascular dementia had an increased risk in hospitalization for a CVE. There was no increase in risk of a CVE for patients treated with quetiapine, olanzapine, or risperidone relative to haloperidol, or for patients receiving olanzapine or risperidone relative to quetiapine. Stratified subgroup analyses demonstrated no difference in risk for CVE-related admission patients with Alzheimer dementia among individual agents. However, patients with vascular dementia receiving risperidone, but not olanzapine or quetiapine, were found to be at decreased risk for CVE admission relative to haloperidol. Conclusions: This study found no increase in overall risk for CVE-related hospital admission in patients treated with antipsychotic medications.
引用
收藏
页码:595 / 601
页数:7
相关论文
共 34 条
[1]  
ALEXOPOULOS GS, 2005, EXPERT CONSENSUS GUI, P1
[2]  
Allison P., 2000, SURVIVAL ANAL USING, P111
[3]   Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients [J].
Barnett, MJ ;
Perry, PJ ;
Alexander, B ;
Kaboli, PJ .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (02) :182-187
[4]  
BEATTIE MC, 1996, DEP VA DATABASES RES, V2
[5]   A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia [J].
Brodaty, H ;
Ames, D ;
Snowdon, J ;
Woodward, M ;
Kirwan, J ;
Clarnette, R ;
Lee, E ;
Lyons, B ;
Grossman, F .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (02) :134-143
[6]   A systematic review of the efficacy and safety of atypical antipsychotics in patients with psychological and behavioral symptoms of dementia [J].
Carson, S ;
McDonagh, MS ;
Peterson, K .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (02) :354-361
[7]  
CAVAZZONI P, 2004, P 44 ANN NEW CLIN DR
[8]  
*COMM SAF MED, 2004, COMM SAF MED ANN REP, P21
[9]   A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia [J].
De Deyn, PP ;
Rabheru, K ;
Rasmussen, A ;
Bocksberger, JP ;
Dautzenberg, PLJ ;
Eriksson, S ;
Lawlor, BA .
NEUROLOGY, 1999, 53 (05) :946-955
[10]  
*DSS, VHA DEC SUPP